NELFINAVIR MESILATE

Nelfinavir Mesilate Adverse Events Reported to the FDA Over Time

How are Nelfinavir Mesilate adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Nelfinavir Mesilate, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Nelfinavir Mesilate is flagged as the suspect drug causing the adverse event.

Most Common Nelfinavir Mesilate Adverse Events Reported to the FDA

What are the most common Nelfinavir Mesilate adverse events reported to the FDA?

Drug Exposure During Pregnancy	88 (10.11%)
Abdominal Distension	23 (2.64%)
Congenital Anomaly	23 (2.64%)
Abdominal Hernia	22 (2.53%)
Cardiac Murmur	22 (2.53%)
Cryptorchism	22 (2.53%)
Lipodystrophy Acquired	18 (2.07%)
Eyelid Ptosis	17 (1.95%)
Anaemia	14 (1.61%)
Premature Baby	13 (1.49%)
Small For Dates Baby	9 (1.03%)
	Show More
Eyelid Function Disorder	7 (.8%)
Facial Wasting	7 (.8%)
Immune Reconstitution Syndrome	7 (.8%)
Maternal Drugs Affecting Foetus	7 (.8%)
No Adverse Event	7 (.8%)
Polydactyly	7 (.8%)
Premature Rupture Of Membranes	7 (.8%)
Atrial Septal Defect	6 (.69%)
Caesarean Section	6 (.69%)
Disseminated Intravascular Coagulat...	6 (.69%)
Foetal Distress Syndrome	6 (.69%)
Hydrocele	6 (.69%)
Intra-uterine Death	6 (.69%)
Mitochondrial Toxicity	6 (.69%)
Pulmonary Embolism	6 (.69%)
Sickle Cell Anaemia	6 (.69%)
Abortion Spontaneous	5 (.57%)
Cleft Palate	5 (.57%)
Depression	5 (.57%)
Diarrhoea	5 (.57%)
Electrocardiogram Qt Prolonged	5 (.57%)
Feeding Disorder Neonatal	5 (.57%)
Foetal Growth Retardation	5 (.57%)
Limb Malformation	5 (.57%)
Pneumocystis Jiroveci Pneumonia	5 (.57%)
Stillbirth	5 (.57%)
Trisomy 21	5 (.57%)
Brain Malformation	4 (.46%)
Diplopia	4 (.46%)
Drug Toxicity	4 (.46%)
Glucose-6-phosphate Dehydrogenase D...	4 (.46%)
Hepatic Cyst	4 (.46%)
Hepatomegaly	4 (.46%)
Hydrocephalus	4 (.46%)
Hydronephrosis	4 (.46%)
Hypospadias	4 (.46%)
Neuropathy Peripheral	4 (.46%)
Neutropenia	4 (.46%)
Pulmonary Artery Stenosis Congenita...	4 (.46%)
Retrognathia	4 (.46%)
Threatened Labour	4 (.46%)
Thrombocytopenia	4 (.46%)
Ventricular Hypertrophy	4 (.46%)
Virologic Failure	4 (.46%)
Vomiting	4 (.46%)
Arnold-chiari Malformation	3 (.34%)
Cd4 Lymphocytes Decreased	3 (.34%)
Convulsion	3 (.34%)
Dermatitis Bullous	3 (.34%)
Drug Interaction	3 (.34%)
Dysphagia	3 (.34%)
Epilepsy	3 (.34%)
Gynaecomastia	3 (.34%)
Haemangioma	3 (.34%)
Hypotonia Neonatal	3 (.34%)
Infection	3 (.34%)
Leukopenia	3 (.34%)
Mental Disorder	3 (.34%)
Microcephaly	3 (.34%)
Ophthalmoplegia	3 (.34%)
Osteonecrosis	3 (.34%)
Pancreatic Carcinoma	3 (.34%)
Paraesthesia	3 (.34%)
Peripheral Sensory Neuropathy	3 (.34%)
Portal Hypertension	3 (.34%)
Premature Labour	3 (.34%)
Progressive External Ophthalmoplegi...	3 (.34%)
Pyloric Stenosis	3 (.34%)
Respiratory Distress	3 (.34%)
Solitary Kidney	3 (.34%)
Splenomegaly	3 (.34%)
Torsade De Pointes	3 (.34%)
Trisomy 15	3 (.34%)
Ventricular Septal Defect	3 (.34%)
Adverse Drug Reaction	2 (.23%)
Apnoea	2 (.23%)
Astrocytoma	2 (.23%)
Astrocytoma, Low Grade	2 (.23%)
Atrioventricular Block Complete	2 (.23%)
Atypical Mycobacterial Infection	2 (.23%)
Body Temperature Fluctuation	2 (.23%)
Bradycardia	2 (.23%)
Bundle Branch Block Left	2 (.23%)
Candidiasis	2 (.23%)
Cholecystitis	2 (.23%)
Congenital Nystagmus	2 (.23%)
Congenital Torticollis	2 (.23%)
Cyanosis Neonatal	2 (.23%)
Death	2 (.23%)
Dermatitis Allergic	2 (.23%)

Share/Embed Graph Export Data

This graph shows the top adverse events submitted to the FDA for Nelfinavir Mesilate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nelfinavir Mesilate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Nelfinavir Mesilate

What are the most common Nelfinavir Mesilate adverse events reported to the FDA?

Chemical Injury And Poisoning	100 (11.49%)
Gastrointestinal Signs	35 (4.02%)
Reproductive Tract And Breast Disor...	34 (3.91%)
Cardiac And Vascular Investigations	27 (3.1%)
Musculoskeletal And Connective Tiss...	27 (3.1%)
Ocular Neuromuscular	27 (3.1%)
Skin And Subcutaneous Tissue	25 (2.87%)
Congenital And Hereditary	24 (2.76%)
Abdominal Hernias And Other Abdomin...	23 (2.64%)
Neonatal And Perinatal Conditions	23 (2.64%)
Hepatic And Hepatobiliary	20 (2.3%)
	Show More
Cardiac Arrhythmias	18 (2.07%)
Therapeutic And Nontherapeutic Effe...	18 (2.07%)
Abortions And Stillbirth	16 (1.84%)
Anemias Nonhemolytic And Marrow Dep...	16 (1.84%)
Cardiac And Vascular Disorders Cong...	16 (1.84%)
Maternal Complications Of Labour An...	14 (1.61%)
Neurological Disorders Congenital	14 (1.61%)
Epidermal And Dermal Conditions	12 (1.38%)
Fetal Complications	12 (1.38%)
Gastrointestinal Tract Disorders Co...	12 (1.38%)
Respiratory	11 (1.26%)
Hematology Investigations	10 (1.15%)
Infections - Pathogen Unspecified	10 (1.15%)
Neurological	10 (1.15%)
Appetite And General Nutritional	9 (1.03%)
Blood And Lymphatic System Disorder...	8 (.92%)
Chromosomal Abnormalities And Abnor...	8 (.92%)
Fungal Infectious	8 (.92%)
Peripheral Neuropathies	8 (.92%)
Immunodeficiency Syndromes	7 (.8%)
Metabolic And Nutritional Disorders...	7 (.8%)
Metabolism	7 (.8%)
White Blood Cell	7 (.8%)
Coagulopathies And Bleeding Diathes...	6 (.69%)
Muscle	6 (.69%)
Obstetric And Gynecological Therape...	6 (.69%)
Pulmonary Vascular	6 (.69%)
Seizures	6 (.69%)
Vision	6 (.69%)
Depressed Mood Disorders	5 (.57%)
Gastrointestinal Motility And Defec...	5 (.57%)
Hepatobiliary	5 (.57%)
Myocardial	5 (.57%)
Pregnancy, Labour, Delivery And Pos...	5 (.57%)
Fatal Outcomes	4 (.46%)
Gastrointestinal Inflammatory Condi...	4 (.46%)
Gastrointestinal Neoplasms Malignan...	4 (.46%)
Increased Intracranial Pressure And...	4 (.46%)
Miscellaneous And Site Unspecified ...	4 (.46%)
Musculoskeletal And Connective Tiss...	4 (.46%)
Neurological, Special Senses And Ps...	4 (.46%)
Placental, Amniotic And Cavity Diso...	4 (.46%)
Platelet	4 (.46%)
Renal Disorders	4 (.46%)
Skin And Subcutaneous Tissue Disord...	4 (.46%)
Spleen, Lymphatic And Reticulendoth...	4 (.46%)
Bone Disorders	3 (.34%)
Breast	3 (.34%)
Coronary Artery	3 (.34%)
Cytoplasmic Disorders Congenital	3 (.34%)
Gastrointestinal Hemorrhages	3 (.34%)
Maternal Complications Of Pregnancy	3 (.34%)
Microbiology And Serology	3 (.34%)
Miscellaneous And Site Unspecified ...	3 (.34%)
Musculoskeletal And Connective Tiss...	3 (.34%)
Ocular Infections, Irritations And ...	3 (.34%)
Psychiatric	3 (.34%)
Renal And Urinary Tract Disorders C...	3 (.34%)
Skin Vascular Abnormalities	3 (.34%)
Bacterial Infectious	2 (.23%)
Bone And Joint Injuries	2 (.23%)
Cutaneous Neoplasms Benign	2 (.23%)
Decreased And Nonspecific Blood Pre...	2 (.23%)
Gallbladder	2 (.23%)
Gastrointestinal Conditions	2 (.23%)
Joint	2 (.23%)
Metabolic, Nutritional And Blood Ga...	2 (.23%)
Metastases	2 (.23%)
Mycobacterial Infectious	2 (.23%)
Neonatal Respiratory	2 (.23%)
Neoplasm Related Morbidities	2 (.23%)
Nervous System Neoplasms Benign	2 (.23%)
Nervous System Neoplasms Malignant ...	2 (.23%)
Neuromuscular	2 (.23%)
Ocular Neoplasms	2 (.23%)
Physical Examination Topics	2 (.23%)
Pleural	2 (.23%)
Protozoal Infectious	2 (.23%)
Urolithiases	2 (.23%)
Anal And Rectal Conditions	1 (.11%)
Anterior Eye Structural Change, Dep...	1 (.11%)
Autoimmune	1 (.11%)
Body Temperature Conditions	1 (.11%)
Cardiac Valve	1 (.11%)
Central Nervous System Vascular	1 (.11%)
Deliria	1 (.11%)
Dental And Gingival Conditions	1 (.11%)
Ear And Labyrinthine Disorders Cong...	1 (.11%)
Embolism And Thrombosis	1 (.11%)
Encephalopathies	1 (.11%)

Share/Embed Graph Export Data

This graph shows the top categories of adverse events submitted to the FDA for Nelfinavir Mesilate, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Nelfinavir Mesilate is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.